Stock fact sheet · data as of
BrainsWay Ltd. (BWAY): fair value, margin of safety and Wheel Score
Healthcare · Medical - Specialties · Israel · ADR · High Growth
Is BWAY undervalued?
At 11.82 (close of 16 Oct 2026), BWAY trades 45% over the GLS average fair value of 8.13, with 2 of 7 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
There is a wide gap between EPV (2.66) and GLS Growth (14.67). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files BWAY under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for BWAY
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 3.24 | -73% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 13.71 | +16% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 5.99 | -49% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 14.67 | +24% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 5.96 | -50% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 10.69 | -10% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 2.66 | -77% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 1.15 | -90% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 19.50 | +65% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
BrainsWay Ltd. scores 6 of 9 on the Piotroski F-score: a middling result that passes the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. On durability BWAY scores 5.0/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.
Returns on capital are moderate - ROIC 9.5%, ROE 10.4%, ROA 6.8% - with debt at 0.09 times equity and a free-cash-flow yield of 1.2%.
BrainsWay Ltd. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 8/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 6 / 9 | ROIC | 9.5% |
|---|---|---|---|
| GLS Moat | 5.0 / 10 | ROE | 10.4% |
| Debt / equity | 0.09 | ROA | 6.8% |
| Free-cash-flow yield | 1.2% | Payout ratio | 0% |
| Institutions | 8 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 33: Weak
With a Wheel Score of 33 BrainsWay Ltd. sits in the Weak band. The parts - Value 0/25, Health 13/20, Moat 8/15, Premium 5/20, Stability 7/20 - show where: Value (0/25) scores lowest.
Implied volatility is 138%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is thin - 502 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 110k shares a day on a market cap of $464M, with a beta of 0.15 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -45% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 8 / 15 | moat 5.0/10 | |
| Premium | 5 / 20 | implied volatility 138% | |
| Stability | 7 / 20 | 110k shares/day, $464M cap, beta 0.15 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 10 Nov 2026 (before the open), 25 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Specialties
The 12 companies below are the closest to BrainsWay Ltd. by market cap within the Medical - Specialties industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| MASS 908 Devices Inc. | 11.89 | 0.2993 | -3872% | 32Weak | $491M |
| SI Shoulder Innovations, Inc. | 17.87 | - | - | 26No options | $372M |
| MLAB Mesa Laboratories, Inc. | 127.74 | 45.24 | -182% | 28No options | $715M |
| ANIK Anika Therapeutics, Inc. | 20.69 | 2.47 | -737% | 40Weak | $277M |
| MOBI Mobia Medical, Inc. Common Stock | 8.31 | - | - | 22No options | $277M |
| LAB Standard BioTools Inc. | 0.6584 | - | - | 36Weak | $258M |
| QDEL QuidelOrtho Corporation | 13.87 | - | - | 45Weak | $951M |
| TRIB Trinity Biotech plc | 6.61 | - | - | 26Weak | $134M |
| NYXH Nyxoah S.A. | 1.19 | - | - | 26No options | $121M |
| APYX Apyx Medical Corporation | 2.56 | - | - | 35Weak | $108M |
| SKIN SkinHealth Systems Inc. | 11.56 | 67.34 | +83% | 45Weak | $75M |
| DRIO DarioHealth Corp. | 5.13 | 119.64 | +96% | 39No options | $50M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BWAY
Is BWAY undervalued right now?
No: at 11.82 the stock trades 45% above the GLS average fair value of 8.13 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of BWAY and what does it mean?
BWAY scores 33 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for BWAY?
8.13 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does BrainsWay Ltd. report earnings next?
The next earnings report is due on 10 Nov 2026 (before the open), 25 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does BWAY have listed options, and how liquid are they?
Yes. The nightly snapshot found 102 listed contracts with 502 open interest across all expiries and implied volatility of 138% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.